This is the accessible text file for GAO report number GAO-04-458T 
entitled 'Public Health Preparedness: Response Capacity Improving, but 
Much Remains to Be Accomplished' which was released on February 12, 
2004.

This text file was formatted by the U.S. General Accounting Office 
(GAO) to be accessible to users with visual impairments, as part of a 
longer term project to improve GAO products' accessibility. Every 
attempt has been made to maintain the structural and data integrity of 
the original printed product. Accessibility features, such as text 
descriptions of tables, consecutively numbered footnotes placed at the 
end of the file, and the text of agency comment letters, are provided 
but may not exactly duplicate the presentation or format of the printed 
version. The portable document format (PDF) file is an exact electronic 
replica of the printed version. We welcome your feedback. Please E-mail 
your comments regarding the contents or accessibility features of this 
document to Webmaster@gao.gov.

This is a work of the U.S. government and is not subject to copyright 
protection in the United States. It may be reproduced and distributed 
in its entirety without further permission from GAO. Because this work 
may contain copyrighted images or other material, permission from the 
copyright holder may be necessary if you wish to reproduce this 
material separately.

Testimony:

Before the Committee on Government Reform, House of Representatives:

United States General Accounting Office:

GAO:

For Release on Delivery Expected at 10:00 a.m. EST:

Thursday, February 12, 2004:

Public Health Preparedness:

Response Capacity Improving, but Much Remains to Be Accomplished:

Statement of Janet Heinrich:

Director, Health Care--Public Health Issues:

GAO-04-458T:

GAO Highlights:

Highlights of GAO-04-458T, a testimony before the Committee on 
Government Reform, House of Representatives 

Why GAO Did This Study:

The anthrax incidents in the fall of 2001 and the severe acute 
respiratory syndrome (SARS) outbreak in 2002-2003 have raised concerns 
about the nation’s ability to respond to a major public health threat, 
whether naturally occurring or the result of bioterrorism. The anthrax 
incidents strained the public health system, including laboratory and 
workforce capacities, at the state and local levels. The SARS outbreak 
highlighted the challenges of responding to new and emerging 
infectious disease. The current influenza season has heightened 
concerns about the nation’s ability to handle a pandemic. 

GAO was asked to examine improvements in state and local preparedness 
for responding to major public health threats and federal and state 
efforts to prepare for an influenza pandemic.

This testimony is based on GAO’s recent report, HHS Bioterrorism 
Preparedness Programs: States Reported Progress but Fell Short of 
Program Goals for 2002, GAO-04-360R (Feb. 10, 2004). This testimony 
also updates information contained in GAO’s report on federal and 
state planning for an influenza pandemic, Influenza Pandemic: Plan 
Needed for Federal and State Response, GAO-01-4 (Oct. 27, 2000).

What GAO Found:

Although states have further developed many important aspects of 
public health preparedness, since April 2003, no state is fully 
prepared to respond to a major public health threat. States have 
improved their disease surveillance systems, laboratory capacity, 
communication capacity, and workforce needed to respond to public 
health threats, but gaps in each remain. Moreover, regional planning 
between states is lacking, and many states lack surge capacity—the 
capacity to evaluate, diagnose, and treat the large numbers of 
patients that would present during a public health emergency. Although 
states are developing plans for receiving and distributing medical 
supplies and material for mass vaccinations from the Strategic 
National Stockpile in the event of a public health emergency, most of 
these plans are not yet finalized.

HHS has not published the federal influenza pandemic plan, and most of 
the state plans have not been finalized. In 2000, GAO recommended that 
HHS complete the national plan for responding to an influenza 
pandemic, but according to HHS, the plan is still under review. Absent 
a federal plan, key questions about the federal role in the purchase, 
distribution, and administration of vaccines and antiviral drugs 
during a pandemic remain unanswered. HHS reports that most states 
continue to develop their state plans despite the lack of a federal 
plan.

What GAO Recommends:

www.gao.gov/cgi-bin/getrpt?GAO-04-458T.

To view the full product, including the scope and methodology, click 
on the link above. For more information, contact Janet Heinrich at 
(202) 512-7119.

[End of section]

Mr. Chairman and Members of the Committee:

I appreciate the opportunity to be here today to discuss the work we 
have done pertaining to the nation's preparedness to manage major 
public health threats. The anthrax incidents in the fall of 2001, the 
SARS[Footnote 1] outbreak in 2002-2003, and the recent incidents 
involving ricin have raised concerns about the nation's ability to 
respond to a major public health threat, whether naturally occurring or 
the result of bioterrorism. The anthrax incidents strained the public 
health system, including surveillance[Footnote 2] and laboratory 
capacities as well as the workforce, at the state and local 
levels.[Footnote 3] The SARS outbreak highlighted the challenges in 
responding to new and emerging infectious disease--especially when the 
ability to identify the disease and a vaccine for preventing it are 
lacking.[Footnote 4] The current influenza season has heightened 
concerns about our nation's ability to handle a pandemic.[Footnote 5] 
The Congress has recognized the need to strengthen the nation's ability 
to respond to such threats and has increased appropriations for 
federal, state, and local public health preparedness efforts. The 
Department of Health and Human Services (HHS) has been developing a 
national plan for responding to an influenza pandemic.

As you requested, to assist the Committee in its consideration of our 
nation's ability to respond to a major public health threat, whether 
naturally occurring or the result of bioterrorism, my remarks today 
will focus on (1) state and local preparedness for responding to major 
public health threats and (2) federal and state efforts to prepare for 
an influenza pandemic.

My testimony today updates testimony that we provided to you in April 
2003[Footnote 6] and is based largely on work we conducted for our 
recently released report on HHS's programs that support state and local 
preparedness for bioterrorism and other public health threats.[Footnote 
7] For that report, we reviewed each state's progress report[Footnote 
8] on the use of bioterrorism preparedness funding distributed in 2002 
by HHS's Centers for Disease Control and Prevention (CDC) and Health 
Resources and Services Administration (HRSA). The progress reports 
covered the period through August 30, 2003, for CDC's program and 
through July 1, 2003, for HRSA's program. For that report we also 
interviewed officials from 10 states, 1 local health department within 
each of these states, and 2 major metropolitan areas directly funded by 
CDC and HRSA. My testimony today also updates information provided in 
our October 2000 report on federal and state planning for an influenza 
pandemic.[Footnote 9] To update that information, in February 2004, we 
spoke with officials from CDC and HHS's National Vaccine Program 
Office. We conducted our work in accordance with generally accepted 
government auditing standards.

In summary, although states have further developed many important 
aspects of public health preparedness, since I testified before you in 
April 2003, no state is fully prepared to respond to a major public 
health threat. States have improved their disease surveillance systems, 
laboratory capacity, communication capacity, and workforce needed to 
respond to public health threats, but gaps in each remain. Moreover, 
regional planning between states is lacking, and many states lack surge 
capacity--the capacity to evaluate, diagnose, and treat the large 
numbers of patients that would present during a public health 
emergency. Although states are developing plans for receiving and 
distributing medical supplies and material for mass vaccinations from 
the Strategic National Stockpile in the event of a public, most of 
these plans are not yet finalized.

HHS has not published the federal influenza pandemic plan, and most of 
the state plans for influenza have not been finalized. In 2000, we 
recommended that HHS complete the national plan for responding to an 
influenza pandemic, but according to HHS, the plan is still under 
review. Absent a federal plan, key questions about the federal role in 
the purchase, distribution, and administration of vaccines and 
antiviral drugs during a pandemic remain unanswered. HHS reports that 
most states continue to develop their state plans despite the lack of a 
federal plan.

Background:

The initial response to a public health emergency--for instance an 
outbreak of an infectious disease--generally occurs at the local and 
state levels and could involve disease surveillance, laboratory 
testing, epidemiologic investigation,[Footnote 10] communication, and 
health care treatment. As a public health emergency develops, each 
plays a critical role in an effective response. Local and state health 
departments collect and monitor data, such as reports from clinicians, 
for disease trends and evidence of an outbreak. Laboratory personnel 
test clinical and environmental samples for possible exposures and 
identification of illnesses. Epidemiologists in the health departments 
use disease surveillance systems to detect clusters of suspicious 
symptoms or diseases in order to facilitate early detection of disease 
and treatment of victims. Public health officials provide needed 
information to the clinical community, other responders, and the public 
and implement control measures to prevent additional cases from 
occurring. Health care providers treat patients and limit the spread of 
infectious disease. All these response activities require a workforce 
that is sufficiently skilled and adequate in number.

The federal government provides funding and resources to state and 
local entities to support preparedness and response efforts. For 
example, in fiscal year 2002 CDC's Public Health Preparedness and 
Response for Bioterrorism cooperative agreement[Footnote 11] program 
provided approximately $918 million to states to improve bioterrorism 
preparedness and response as well as other public health emergency 
preparedness capacities. Similarly, HRSA's Bioterrorism Hospital 
Preparedness cooperative agreement program provided approximately $125 
million to states in fiscal year 2002 to enhance the capacity of 
hospitals and associated health care entities to respond to 
bioterrorist attacks. HHS renewed these cooperative agreements for the 
period of August 31, 2003 through August 30, 2004. For these renewed 
agreements, CDC's program and HRSA's program distributed about $870 
million and about $498 million, respectively. Among the other resources 
that the federal government provides is the Strategic National 
Stockpile, which contains pharmaceuticals and medical supplies that can 
be delivered to the site of a public health emergency anywhere in the 
United States within 12 hours of the decision to deploy them.

The federal government also supports preparedness efforts for an 
influenza pandemic. HHS's National Vaccine Program Office is 
responsible for the development of federal plans for vaccine and 
immunization activities and coordinating these efforts among federal 
agencies. To foster state and local planning, HHS issued interim 
planning guidance for the states in 1997 that outlined general federal 
and state responsibilities during an influenza pandemic. HHS expects 
that if a pandemic occurs, both the vaccines that are used to prevent 
influenza and the antiviral drugs that are used to treat influenza will 
be in short supply.[Footnote 12] The guidance discussed certain key 
issues related to limited supplies of the influenza vaccine and 
antiviral drugs--for instance the amount of vaccine and antiviral drugs 
that will be purchased at the federal level; the division of 
responsibility between the public and private sectors for the purchase, 
distribution, and administration of these supplies during a pandemic; 
and priorities for vaccinating population groups, such as health 
workers and public health personnel involved in the pandemic response, 
and persons traditionally considered to be at increased risk of severe 
influenza illness and mortality.

States Have Further Developed Important Aspects of Public Health 
Preparedness, but Additional Work Is Needed:

States reported that as of the summer of 2003 they have made 
improvements in their preparedness to respond to major public health 
threats, but no aspect of preparedness has been fully addressed by all 
of the states.[Footnote 13] Specifically, although states have 
strengthened their disease surveillance systems, laboratory capacity, 
communications, workforce, surge capacity, regional coordination 
across state borders, and readiness to utilize the Strategic National 
Stockpile, all of these important aspects of preparedness require 
additional work.

Disease Surveillance Systems:

Although some states have made improvements to their disease 
surveillance systems, the nation's ability to detect and report a 
disease outbreak is not uniformly strong across all states. For 
example, about half of the states reported that their health 
departments are capable of receiving and evaluating urgent disease 
reports on a 24-hour-per-day, 7-day-per-week basis; however, few states 
reported having the ability to rapidly detect an outbreak of an 
influenza-like illness in the state. Similarly, few states reported 
efforts to strengthen links between their public health and animal 
surveillance systems[Footnote 14] and the veterinary community in order 
to monitor diseases in animals that may be spread to humans, such as 
the West Nile virus.[Footnote 15]

Laboratory Capacity:

States have increased their capacity to test and identify specimens and 
improve laboratory security, although laboratory capacity is not 
uniformly robust in all states. All states participate in CDC's 
Laboratory Response Network, a network of local, state, federal, and 
international laboratories that are equipped to respond to biological 
and chemical terrorism, emerging infectious diseases and other public 
health threats. However, only about half of the states reported that 
they have at least one public health laboratory within the state that 
has the appropriate instrumentation and appropriately trained staff to 
conduct certain tests for rapidly detecting and correctly identifying 
biological agents. About half of the states reported that they had a 
facility with a biosafety level sufficient to handle such agents as 
anthrax.[Footnote 16] About half the states also reported that 
laboratory security within the state is consistent with HHS guidelines, 
which include recommendations for protecting laboratory personnel and 
preventing the unauthorized removal of dangerous biologic agents from 
the laboratory.

Communication:

Although improving, communication, both among those involved in 
responding to a major public health threat--such as public health 
officials, health care providers, and emergency management agencies--
and with the public, remains a challenge. CDC's Health Alert Network 
has been expanded--most of the states reported that the local health 
departments that cover at least 90 percent of their populations are 
involved in this network.[Footnote 17] However, many states reported 
that they were still in the process of assessing their communication 
needs. Although about half the states have a plan for educating the 
public about the risks posed by bioterrorism and other public health 
threats, few states have mechanisms in place for communicating with the 
general public during an incident about such issues as when it is 
necessary to go to the hospital.

Workforce:

States have increased the number of personnel essential to public 
health preparedness, but concerns about workforce shortages remain. 
Most of the states reported that the bioterrorism preparedness funding 
from CDC allowed each to appoint an executive director of its 
bioterrorism preparedness and response program, to designate a response 
coordinator, and to hire at least one epidemiologist for each 
metropolitan area with a population greater than 500,000. However, most 
states continue to have staffing concerns. As we have reported 
previously,[Footnote 18] some state and local health officials have had 
difficulty finding and hiring epidemiologists and laboratory personnel. 
The ability to hire and retain personnel in these areas is still a 
concern for state and local health officials, who identify workforce 
shortages as a long-term challenge to their preparedness efforts.

Surge Capacity:

Most states lack surge capacity--that is, the capacity to respond to 
the large influx of patients that could occur during a public health 
emergency. For example, few states reported that they had the capacity 
to evaluate, diagnose, and treat 500 or more patients involved in a 
single incident. Furthermore, no state reported having protocols in 
place for augmenting personnel in response to large influxes of 
patients, and few states reported having plans for sharing clinical 
personnel among hospitals. In addition, few states reported having the 
capacity to rapidly establish clinics to immunize or provide treatment 
to large numbers of patients.

Regional Planning:

Few states have regional plans in place that would coordinate the 
response among states during a public health emergency, and state 
officials remain concerned about a lack of regional planning across 
state borders. Few states have completed regional response plans for 
incidents of bioterrorism and other public health threats and 
emergencies. Most of the states that do have such plans have not 
established training programs to support their plans or mechanisms to 
test their plans.

Strategic National Stockpile:

Most state plans for using the Strategic National Stockpile in the 
event of a public health emergency have not been fully developed. All 
states have prepared preliminary plans for the receipt and management 
of stockpile materials, but only about a third of the states have plans 
that outline how they would distribute antibiotics, chemical/nerve 
agent antidotes, and other materials to areas within the state.

The Federal Influenza Plan Has Not Been Finalized, but State Planning 
and Other Efforts Continue:

Federal officials have not finalized plans for responding to an 
influenza pandemic, and state influenza pandemic response plans are in 
various stages of completion.

As we have reported previously,[Footnote 19] federal officials have 
drafted but not finalized the federal influenza pandemic plan. In 2000, 
we recommended that HHS complete the national plan for responding to an 
influenza pandemic, but HHS reported recently that the plan was still 
under review within HHS. However, HHS is taking other steps to prepare 
for an influenza pandemic. For example, CDC has increased the supply of 
ventilators and added an antiviral drug to the Strategic National 
Stockpile. HHS is also coordinating with other federal partners, such 
as the Department of Agriculture, to improve the nation's ability to 
respond to public health emergencies involving the veterinary and 
agricultural sectors.

Despite the absence of a finalized, federal response plan for an 
influenza pandemic, states are developing their own response plans. 
According to HHS officials, as of February 2004, 15 states have final 
or draft plans, and 34 states are actively working on plans. In these 
plans, states have had to make assumptions about what the federal role 
during an influenza pandemic will be. It is still unclear whether the 
private sector, the public sector, or both will have responsibility for 
purchasing and distributing vaccines and antiviral drugs. Some states 
have assumed that vaccine supply will be under the control of the 
federal government, while others have assumed that it will not. States 
have also made different assumptions about who will pay for vaccines, 
antiviral medications, and related supplies.

Concluding Observations:

States have taken many actions to improve their ability to respond to a 
major public health threat, but no state has reported being fully 
prepared. Federal plans for the purchase, distribution, and 
administration of vaccines and drugs in response to an influenza 
pandemic still have not been finalized, complicating the efforts of 
states to develop their state plans and heightening concern about our 
nation's ability to respond effectively to an influenza pandemic. 
States are more prepared now, but much remains to be accomplished.

Mr. Chairman, this completes my prepared statement. I would be happy to 
respond to any questions you or other Members of the Committee may have 
at this time.

Contact and Acknowledgments:

For further information about this testimony, please contact Janet 
Heinrich at (202) 512-7119. Angela Choy, Maria Hewitt, Krister Friday, 
Nkeruka Okonmah, and Michele Orza also made key contributions to this 
statement.

FOOTNOTES

[1] SARS is the abbreviation for severe acute respiratory syndrome.

[2] Public health surveillance uses systems that provide for the 
ongoing collection, analysis, and dissemination of health-related data 
to identify, prevent, and control disease.

[3] See U.S. General Accounting Office, Bioterrorism: Public Health 
Response to Anthrax Incidents of 2001, GAO-04-152 (Washington, D.C.: 
Oct. 15, 2003).

[4] See U.S. General Accounting Office, SARS Outbreak: Improvements to 
Public Health Capacity Are Needed for Responding to Bioterrorism and 
Emerging Infectious Diseases, GAO-03-769T (Washington, D.C.: May 7, 
2003).

[5] Pandemics are worldwide epidemics. Influenza pandemics can have 
successive "waves" of disease and last for up to 3 years. Three 
pandemics occurred in the 20th century: the "Spanish flu" of 1918, 
which killed at least 20 million people worldwide; the "Asian flu" of 
1957; and the "Hong Kong flu" of 1968.

[6] U.S. General Accounting Office, Infectious Disease Outbreaks: 
Bioterrorism Preparedness Efforts Have Improved Public Health Response 
Capacity, but Gaps Remain, GAO-03-654T (Washington, D.C.: Apr. 9, 
2003).

[7] U.S. General Accounting Office, HHS Bioterrorism Preparedness 
Programs: States Reported Progress but Fell Short of Program Goals for 
2002, GAO-04-360R (Washington, D.C.: Feb. 10, 2004).

[8] The progress reports were for the 50 states, the District of 
Columbia, and the nation's three largest municipalities (New York City, 
Chicago, and Los Angeles County).

[9] U.S. General Accounting Office, Influenza Pandemic: Plan Needed for 
Federal and State Response, GAO-01-4 (Washington, D.C.: Oct. 27, 2000).

[10] Epidemiology is the study of how disease is distributed in 
populations and the factors that influence or determine this 
distribution.

[11] A cooperative agreement is used as a mechanism to provide 
financial support for a particular activity when substantial 
interaction is expected between the executive agency and a state, local 
government, or other recipient carrying out the funded activity.

[12] These shortages are expected because demand would exceed current 
rates of production and because manufacturers report that increasing 
the production capacity of antiviral drugs can take at least 6 to 9 
months. 

[13] In this section, "state" refers to the 50 states, the District of 
Columbia, New York City, Chicago and Los Angeles County.

[14] Animal health surveillance involves the collection, evaluation, 
and interpretation of data to provide timely and accurate detection, 
diagnosis, prevention, and control of diseases in animals.

[15] For more information, see U.S. General Accounting Office, West 
Nile Virus Outbreak: Lessons for Public Health Preparedness, GAO/
HEHS-00-180 (Washington, D.C.: Sept. 11, 2000).

[16] Biosafety measures the degree of protection a laboratory offers to 
personnel, the environment, and the community. 

[17] The Health Alert Network is a nationwide program designed to 
ensure communication capacity at all state and local health 
departments. This network enables local health departments to receive 
health alerts and other information from CDC and state health 
departments.

[18] U.S. General Accounting Office, Bioterrorism: Preparedness Varied 
across State and Local Jurisdictions, GAO-03-373 (Washington, D.C.: 
Apr. 7, 2003); GAO-04-360R; GAO-03-654T.

[19] GAO-01-4; GAO-03-654T.